hep C

What's missing in hep C drugsPayers have unmet needs in the changing hepatitis C (HCV) space, according to a recent survey. The survey, from Precision for Value, highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
New strategies for managing drug spend: RA, Cancer, Hep C
New strategies for managing drug spend: RA, Cancer, Hep CThe proliferation of specialty drugs has prompted new techniques for keeping costs in tow.
FDA approves Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C infectionFDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis.
Three ways to rein in drug costs regardless of who becomes presidentIt’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.
Insurer expands hep C drug coverageNationwide class action suit spurs new coverage decision for hepatitis C medications.
Opinion: Top 4 lessons learned from Asembia 2016Insights from the 2016 edition of the largest gathering in specialty pharmacy.
New diagnostic tests help physicians predict HCV drug resistanceHep C virus testing supports value of diagnostics in precision medicine.
FDA expands use of hep C drugFDA has approved expanded use of daclatasvir (Daklinza, Bristol-Myers Squibb) in combination with Gilead Sciences' Sovaldi (sofosbuvir), for the treatment of patients with chronic hepatitis C (HCV) genotype 1 or 3.
5 things to know about Gilead’s new hep C drugGilead Sciences, which already makes the leading hepatitis C drugs Harvoni and Sovaldi, recently received priority review from FDA for a new Hepatitis C combination drug.
Watch list 2016: Top therapeutic areas
Watch list 2016: Top therapeutic areasExperts say you should follow these 6 therapeutic areas.